scholarly article | Q13442814 |
P356 | DOI | 10.1002/EJHF.1437 |
P698 | PubMed publication ID | 30843353 |
P50 | author | Nicolas Girerd | Q56394664 |
Leong L Ng | Q61120317 | ||
Adriaan A Voors | Q91537232 | ||
Joachim Struck | Q91631606 | ||
Biniyam G Demissei | Q91665607 | ||
Stefan D Anker | Q93002591 | ||
Jozine M Ter Maaten | Q114321777 | ||
Daan Kremer | Q114429154 | ||
Nilesh Samani | Q19665717 | ||
Marco Metra | Q39274051 | ||
Chim C. Lang | Q41297830 | ||
Kenneth Dickstein | Q43248428 | ||
P2093 | author name string | Andreas Bergmann | |
John Cleland | |||
Dirk J van Veldhuisen | |||
Simon P R Romaine | |||
P2860 | cites work | Increased plasma levels of adrenomedullin in patients with heart failure | Q71827359 |
Elevation of Circulating and Ventricular Adrenomedullin in Human Congestive Heart Failure | Q71955928 | ||
Differential responses of circulating and tissue adrenomedullin and gene expression to volume overload | Q74044863 | ||
Tackling Early Heart Failure Deaths and Readmissions by Estimating Congestion | Q86635582 | ||
Bio-adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure | Q89186716 | ||
Adrenomedullin in heart failure: pathophysiology and therapeutic application | Q90789256 | ||
Sandwich Immunoassay for Bioactive Plasma Adrenomedullin | Q97416560 | ||
Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. | Q33750991 | ||
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the | Q34640762 | ||
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib | Q34677347 | ||
Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure | Q36578779 | ||
Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock | Q38382864 | ||
Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure | Q38391668 | ||
Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Em | Q38496703 | ||
Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study | Q40280356 | ||
Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure | Q40313672 | ||
A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. | Q40777024 | ||
FGF23 regulates renal sodium handling and blood pressure | Q42952198 | ||
Vascular endothelial adrenomedullin-RAMP2 system is essential for vascular integrity and organ homeostasis | Q43639160 | ||
Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial | Q44622051 | ||
Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF. | Q48741780 | ||
Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure | Q48742018 | ||
Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey | Q49954448 | ||
Effects of the Humanized Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) on Vascular Barrier Function and Survival in Rodent Models of Systemic Inflammation and Sepsis | Q50086305 | ||
Vascular Effects of Adrenomedullin and the Anti-Adrenomedullin Antibody Adrecizumab in Sepsis | Q50086313 | ||
Adrenomedullin and endothelial barrier function. | Q52922207 | ||
Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. | Q54125748 | ||
P433 | issue | 6 | |
P304 | page(s) | 732-743 | |
P577 | publication date | 2019-03-06 | |
P1433 | published in | European Journal of Heart Failure | Q5017954 |
P1476 | title | Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure | |
P478 | volume | 21 |
Q92099993 | Adrenomedullin, a circulating biomarker of congestion: in search of evidence |
Q93332917 | April 2020 at a glance: epidemiology, prevention, and biomarkers |
Q96585882 | Bioactive adrenomedullin in plasma is associated to biventricular filling pressures in patients with advanced heart failure |
Q91631616 | Circulating Biologically Active Adrenomedullin Predicts Organ Failure and Mortality in Sepsis |
Q91662964 | Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission |
Q94948551 | Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment |
Q90022431 | Fibroblast growth factor 23 and the quest for the Holy Grail in heart failure: will the Crusaders be forced to surrender? |
Q104074195 | Heart failure in the last year: progress and perspective |
Q89459313 | Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction |
Q92925805 | June 2019 at a glance: from genetics to haemodynamics, biomarkers and imaging for the prediction of outcomes |
Search more.